Immunotherapy plus chemotherapy with or without blood pressure medicine for colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a blood pressure medicine (propranolol) to immunotherapy and chemotherapy works better for locally advanced colon cancer. You would receive treatment before surgery to shrink your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Colon cancer confirmed by biopsy with a specific genetic marker (pMMR/MSS) and no prior cancer treatment
- Cancer is advanced (T4 or T3 with lymph node spread) and located at least 4 inches from the anus
- No cancer spread to distant organs (liver, lungs, etc.)
- Age 18–75 with good overall health and adequate organ function (blood counts, kidney, liver)
- Normal heart rhythm and blood pressure between 100–150 / 60–90 mmHg; normal thyroid function
- Able to follow study procedures and come to regular appointments for at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with high-risk MSS colon cancer. It is for patients who have not yet received treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus bevacizumab (a targeted therapy) and alternating chemotherapy regimens as a first treatment for advanced colorectal cancer that cannot be removed by surgery. It aims to see if this combination is safe and effective.
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This trial tests adding a blood pressure medicine (propranolol) to standard chemotherapy and immunotherapy before surgery for locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
This trial tests whether a stronger chemo combination plus an immunotherapy drug (PD-1 inhibitor) works better than standard chemo alone when given before surgery for locally advanced colon cancer. It aims to shrink the tumor and improve outcomes.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (a checkpoint inhibitor) before surgery helps shrink locally advanced colon cancer. It is for people with a specific tumor type (MSS and RAS mutation) who have not had prior treatment.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.